A Physiologically Based Pharmacokinetic Model to Predict Systemic Ondansetron Concentration in Liver Cirrhosis Patients.

Faleh AlqahtaniAbdullah H AlruwailiMohammed S AlasmariSultan A AlmazroaKhaled S AlsuhaibaniMuhammad Fawad RasoolAbdulkarim F AlruwailiSary Alsanea

Published in: Pharmaceuticals (Basel, Switzerland) (2023)

In this study, the developed PBPK model has described the pharmacokinetics of ondansetron successfully. The PBPK model has been successfully evaluated to be used as a tool for dose adjustments in liver cirrhosis patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis